Clinical outcomes and immune phenotypes associated with STK11 co-occurring mutations in non-small cell lung cancer

被引:14
|
作者
Malhotra, Jyoti [1 ]
Ryan, Brid [2 ]
Patel, Malini [1 ]
Chan, Nancy [1 ]
Guo, Yanxiang [1 ]
Aisner, Joseph [1 ]
Jabbour, Salma K. [1 ]
Pine, Sharon [1 ]
机构
[1] Rutgers Canc Inst New Jersey, 195 Little Albany St, New Brunswick, NJ 08903 USA
[2] NCI, Bethesda, MD 20892 USA
关键词
STK11; co-mutations; phenotypes; outcomes; CONSOLIDATION; STK11; KRAS; CARBOPLATIN; CONCURRENT; CISPLATIN; PROFILES; NSCLC; TP53;
D O I
10.21037/jtd-21-1377
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: STK11 mutation in non-small cell lung cancer (NSCLC) is associated with worse survival as well as primary resistance to PD-1/PD-L1 targeting immunotherapy. We hypothesize that co-occurring mutations and tumor mutation burden (TMB) may impact response to therapy and prognosis. Methods: Forty-one patients with STK11-mutated NSCLC seen in our Thoracic oncology clinic with available next-generation sequencing tumor data were included in the analysis. Data from the Cancer Genome Atlas (TCGA) was used for survival and immune gene expression analysis. Overall and progression free survival (PFS) was estimated by the Kaplan-Meier method and compared using a log-rank test. Results: In the 41 patients included, common co-occurring alterations with STK11 were KRAS (54%), TP53 (44%), CDKN2A (37%) and KEAP1 (27%). Overall 17 patients received locoregional therapy with surgery or radiation with median OS of 8.6 years and there was no significant difference in clinical outcomes with KRAS and TP53 co-occurring mutations. Response to both chemotherapy and immunotherapy was poor across all co-occurring mutations. However, TP53 co-mutation was associated with improved clinical benefit with immunotherapy. Patients with higher TMB had longer PFS with immunotherapy. In TCGA survival analysis, tumors with STK11 mutation with or without KRAS co-mutation were associated with worse survival (P<0.05) but tumors with STK11/TP53 co-mutation did not have worst survival compared to STK11 wild type tumors. Moreover, co-occurring mutations had significant effect on intratumoral immune status with both STK11 alone and STK11/KRAS co-mutated tumors showing more enrichment for wound healing immune subtype while STK11/TP53 co-mutated tumors showed more enrichment for IFN-g immune subtype. Conclusions: Our retrospective analysis in patients with STK11-mutated NSCLC found that both TMB and co-occurring mutations may be predictors for response to immunotherapy with worse outcomes in patients with low TMB or KRAS co-mutation and improved outcomes with TP53 co-mutation. Patients with STK11-mutated NSCLC also demonstrate chemotherapy resistance but have similar outcomes with localized treatment compared to STK11 wild type tumors. Moreover, co-mutations with KRAS or TP53 significantly alter tumor immune landscape of STK11-mutated tumors and therefore response to immunotherapy.
引用
收藏
页码:1772 / 1783
页数:12
相关论文
共 50 条
  • [1] Impact of STK11 and KRAS co-mutations on outcomes with immunotherapy in non-small cell lung cancer.
    Basher, Fahmin
    Saravia, Diana
    Fanfan, Dino
    Cotta, Jared Addison
    Lopes, Gilberto
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Clinical immune and genomic profiling of STK11 mutant non-squamous non-small cell lung cancer
    Yau, Edwin
    Pabla, Sarabjot
    Glenn, Sean
    Papanicolau-Sengos, Antonios
    Nesline, Mary
    Dy, Grace
    Morrison, Carl
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [3] Prevalence of STK11, KEAP1, and KRAS mutations/co-mutations and associated clinical outcomes for patients newly diagnosed with metastatic non-small cell lung cancer
    Dabbous, Firas
    Wang, Ching-Yu
    Simmons, Daniel
    Huse, Samuel
    Jassim, Rami
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] STK11 mutations in non-small cell lung cancer (NSCLC): descriptive analysis and prognostic significance
    Facchinetti, Francesco
    Bluthgen, Maria Virginia
    Clain, Gabrielle Tergemina
    Faivre, Laura
    Pignon, Jean-Pierre
    Planchard, David
    Soria, Jean-Charles
    Besse, Benjamin
    Lacroix, Ludovic
    [J]. CANCER RESEARCH, 2016, 76
  • [5] Multi-omics Analysis of Immune Determinants of STK11 in Non-Small Cell Lung Cancer
    Alhushki, S. K.
    Al-Muhtaseb, A.
    Abushukair, H.
    Abulrous, F.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S442 - S443
  • [6] Mutations of the LKB1/STK11 gene in non-small cell lung cancer with loss of heterozygosity
    Yang, Sei-Hoon
    Meerzaman, Daoud
    Mechanic, Leah E.
    Gill, Rajbir
    Dracheva, Tatiana
    Han, Seung-Bum
    Kim, Sam-Yong
    Bowman, Elise D.
    Harris, Curtis C.
    Jen, Jin
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 246 - 246
  • [7] Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer
    Rosellini, Pietro
    Amintas, Samuel
    Caumont, Charline
    Veillon, Remi
    Galland-Girodet, Sigolene
    Cuguilliere, Alain
    Nguyen, Laurent
    Domblides, Charlotte
    Gouverneur, Amandine
    Merlio, Jean-Philippe
    Bezin, Julien
    Girodet, Pierre-Olivier
    [J]. EUROPEAN JOURNAL OF CANCER, 2022, 172 : 85 - 95
  • [8] Role of STK11 in ALK-positive non-small cell lung cancer
    Zhou, Wen
    Yan, Lu-Da
    Yu, Zhi-Qiong
    Li, Na
    Yang, Yong-Hua
    Wang, Meng
    Chen, Yuan-Yuan
    Mao, Meng-Xia
    Peng, Xiao-Chun
    Cai, Jun
    [J]. ONCOLOGY LETTERS, 2022, 23 (06)
  • [9] Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a STK11 mutation
    An, Josiah
    Yan, Melissa
    Yu, Nanmeng
    Chennamadhavuni, Adithya
    Furqan, Muhammad
    Mott, Sarah L.
    Loeffler, Bradley T.
    Kruser, Timothy
    Sita, Timothy L.
    Feldman, Lawrence
    Nguyen, Ryan
    Pasquinelli, Mary
    Hanna, Nasser H.
    Abu Hejleh, Taher
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (08) : 3608 - 3615
  • [10] Serine/threonine kinase 11 (STK11) mutations and immunotherapy resistance in patients with non-small cell lung cancer.
    Uba, Richie
    Raez, Luis E.
    Dumais, Katerine
    Gentile, Frank
    Powery, Herman W.
    Domingo, Gelenis Calzadilla
    Izquierdo, Paola
    Hunis, Brian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)